Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Drug Manufacturers - Major
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11

Business Wire January 8, 2016

Merck (MRK) CEO itching to make acquisition deals in pharma space

Canadian Press January 5, 2016

Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis

Business Wire January 5, 2016

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection

Business Wire January 5, 2016

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection

Business Wire January 4, 2016

Peering Through The Fog To Find The Best Sectors Into Year End

Benzinga.com  December 23, 2015

An Award-Winning Debut For This Goldman ETF

Benzinga.com  December 23, 2015

Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Business Wire December 17, 2015

Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting

Business Wire December 8, 2015

Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya(TM) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Canada NewsWire December 7, 2015

European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C

Business Wire December 4, 2015

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1

Business Wire November 24, 2015

European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Business Wire November 23, 2015

Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia

Business Wire November 16, 2015

Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies

Business Wire November 14, 2015

Gilead Presents New Data at The Liver Meeting 2015

Business Wire November 14, 2015

U.S. FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C

Business Wire November 12, 2015

Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10

Business Wire November 9, 2015

Genvoya, new four in one daily HIV pill made by Gilead Sciences, wins approval by FDA

Canadian Press November 6, 2015

U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Business Wire November 5, 2015

Podcasts